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Abstract
Background: Novel and targetable mutations are needed for improved understanding and treatment of lung
cancer in never-smokers.
Methods: Twenty-seven lung adenocarcinomas from never-smokers were sequenced by both exome and mRNA-seq
with respective normal tissues. Somatic mutations were detected and compared with pathway deregulation, tumor
phenotypes and clinical outcomes.
Results: Although somatic mutations in DNA or mRNA ranged from hundreds to thousands in each tumor, the
overlap mutations between the two were only a few to a couple of hundreds. The number of somatic mutations
from either DNA or mRNA was not significantly associated with clinical variables; however, the number of overlap
mutations was associated with cancer subtype. These overlap mutants were preferentially expressed in mRNA with
consistently higher allele frequency in mRNA than in DNA. Ten genes (EGFR, TP53, KRAS, RPS6KB2, ATXN2, DHX9,
PTPN13, SP1, SPTAN1 and MYOF) had recurrent mutations and these mutations were highly correlated with
pathway deregulation and patient survival.
Conclusions: The recurrent mutations present in both DNA and RNA are likely the driver for tumor biology,
pathway deregulation and clinical outcomes. The information may be used for patient stratification and
therapeutic target development.
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Background
Lung cancer in never smokers becomes one of the major
health burdens. Majority of primary lung cancer in never
smokers is adenocarcinoma, which has distinct genetic
and molecular profiles as well as demographic and clinical
characteristics compared to those observed in smokers
[1]. While EGFR (epidermal growth factor receptor) is
commonly mutated in adenocarcinoma of never smoker
patients, the mutations in other genes are much less
common than in the smoker patients [2]. Mutations in
genes such as HER2, EML4-ALK, KRAS and BRAF are
all very low with mutation rate of 4.6% 4.3%, 2.0%, and
0.6%, respectively [3]. Rigorous search for new mutations
and treatment targets have been carried out during the
past few years with the latest next generation sequencing
technology such as whole genome or targeted exome
sequencing. A study of 183 lung adenocarcinomas by
exome-sequencing with 27 never smokers included
confirms the mutation profile differences between never
smokers and smokers [4]. However, the recurrent muta-
tions in never smokers (> = 2 samples, out of 2,528 somatic
point mutations) are only detected in three genes, EGFR,
TBL3 and HSD17B7P2 in the data. In the larger TCGA
(The Cancer Genome Atlas) data with 41 never smokers,
only 8 recurrent mutations (out of 1,306 point mutations)
in 8 genes (C21orf99, FAM182B, CCDC144C, FLJ36000,
DDX11L2, EEF1B2, FRG1B, and EGFR) are reported.
However, the functional impacts and clinical relevance of
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these genes have not been further investigated. The low
frequency of recurrent mutations and the little overlap of
mutated genes (except EGFR) across the studies may sug-
gest the mutational drivers for lung cancer in never
smokers can be diverse and highly individualized. It is also
noted that majority of mutations in cancers are random
noise or passenger mutations due to a high rate of DNA
replication and compromised DNA repair system, which
do not play a significant role in cancer development, pro-
gression or patient outcomes. Distinguishing the driver
from passenger mutations is challenging and the common
approaches are to identify those genes harboring more
mutations than expected given the average background
mutation frequency for the cancer type. The approach can
generate a long list with the sample number increasing,
many of which are likely false [5]. Although this may be
mitigated by incorporating mutation rate heterogeneity by
a newly proposed method [5], it requires a large number
of samples to be more reliable.
Most tumor somatic mutations are detected from DNA
although about a third of the genes are not expressed in a
particular tissue. The genes that are not expected to be
expressed at all in a particular tissue or tumor (i.e., except
the genes that are turned off abnormally) less likely have
an important role in tumor development and progression
and the mutations in these genes therefore may be less
likely functional. Additionally, evidence shows that se-
lective pressure against protein-altering mutations in
expressed genes, may lead to passenger mutations more
enriched in unexpressed genes as reported in a case of lung
cancer [6]. For the genes with mutations in DNA, some
may just be random noises not passed on to RNA to affect
protein translation due to the effects of transcription-
coupled repair [7]. In this study, we hypothesized that mu-
tations present in both DNA and RNA of adenocarcinoma
of the lung in never smokers were more likely func-
tional in driving tumor biology and tested the hypoth-
esis using 27 tumor and normal pairs with both
exome-seq and mRNA-seq. We found 282 mutations
in 262 genes and 10 genes with recurrent mutations.
These mutated genes were highly enriched in cancer
development and progression processes. The overlap
mutations between DNA and mRNA were better cor-
related with clinical variables. More importantly the
conserved recurrent mutations in the 10 genes were
highly correlated with pathway deregulation, which
further predicted patient clinical outcomes.
Methods
Experimental design
Twenty-seven lung cancer patients with stage I adeno-
carcinoma from never smokers were selected from the
Genetics and Epidemiology of Lung Cancer Program
database at Mayo Clinic. The eligible patients were those
who were enrolled from 1998 to 2008 with surgery and
stored fresh frozen tumor and normal lung tissues. The
written consents for participating in the study were ob-
tained and the study protocols were approved by the
Mayo Clinic Institutional Review Boards. A pair of fresh
frozen tissue, one from the primary tumor and another
from the unaffected normal lung, was cut, stained, and
reviewed by an experienced pathologist to make sure each
case’s correct diagnosis and sufficient tumor component
(greater than 70%) to be eligible for the study. The tumor
components were marked and macro-dissected from the
same tissue block for DNA and RNA extraction.
Exome-seq and analysis
Exonic sequencing was enriched using Agilent’s SureSelect
technology (version 2), which targets 51 Mb of sequence
from 212,911 exons and their flanking regions in ∼ 20,000
genes. The purified capture products were then amplified
using the SureSelect GA PCR primers (Agilent) for 12
cycles. Sequencing was carried out with HiSeq 2000
using 100-bp paired-end reads.
Somatic mutations between the paired tumor and normal
sample for each patient were called using our customized
analytical pipeline, TREAT [8]. Briefly, the raw sequence
reads in FASTQ format were aligned to a human reference
genome (NCBI human genome assembly build 37) using
BWA [9]. The PCR duplicates were detected and removed
by Picard (http://picard.sourceforge.net). Further local re-
alignment and recalibration were conducted by GATK [10].
Single sample SNVs were called by SNVmix [11] and
INDELs by GATK. Somatic mutations between the paired
tumor and normal were called using VarScan 2 (version
2.2.11) [12] with following criteria: minimum coverage for
normal 8, minimum coverage for tumor 6, tumor purity
0.8, somatic p value less than 0.05. The SNVs were anno-
tated by ANNOVAR [13] and functional impacts were pre-
dicted by combination of SIFT [14] and POLYPHEN [15].
mRNA-seq and data analysis
Total RNA extraction was performed using Exiqon’s
miRCURY RNA Isolation Kit. The pair end sequencing
was carried out using the Illumina HiSeq 2000 sequencer
at 100 bps.
Sequence reads in fastq format were processed using
our internal RNA-seq pipeline. The reads were aligned
to the human genome build 37 using TopHat (1.3.3)
with Bowtie (0.12.7) [16,17]. HTSeq (0.5.3p3,) was used
to perform gene counting while BEDTools (2.7.1) [18] was
used to count the reads mapping to individual exons. Dif-
ferential gene expression was identified at raw gene count
using edgeR [19]. For analyses that compared relative ex-
pression across genes or pathway deregulation analysis,
log2 RPKM (reads per kilobase per million mapped reads)
normalized data [20] was used.
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For somatic mutations from the mRNA-seq, we first
removed all reads that were not uniquely mapped to the
genome and any reads that were marked as duplicates
from above aligned bam file. The somatic mutations
were called using VarScan2 (version 2.2.11) comparing
tumor and its paired normal directly at each position
with sufficient coverage with the same parameters as the
exome-seq data, i.e., the minimum coverage for normal
8, minimum coverage for tumor 6, tumor purity 0.8, and
somatic p value less than 0.05. The mutation calls were
annotated by ANNOVAR [13].
The overlap mutations between the DNA and the
RNA were found by comparing the mutations detected
from each at the exact same genomic location and with
the same mutated allele. Only non-synonymous mutations
were kept for further downstream analyses.
Pathway deregulation analysis by mRNA-seq data
A gene mutation may not necessarily cause its expres-
sion change. However, it may lead to abnormal inter-
action with other proteins in a pathway or network.
Instead of gene focused analysis, we conducted path-
way deregulation assessment for each tumor on 814
pathways characterized in the KEGG, REACTOME and
BIOCARTA database with “pathifier” [21]. We started
with the RPKM normalized gene expression data for
both tumor and normal and a pathway deregulation
score for each pathway in each sample was calculated
using the normal samples as reference. Once the scores
were obtained, we filtered out pathways with no much
variation across 27 tumors and kept 272 pathways with
pathway score standard deviation greater than 0.2 for
unsupervised clustering, which used 1-Pearson correlation
as distance matrix and centroid as linkage method. The
formed sample clusters by pathway deregulation severity
scores were used to correlate with clinical variables and
patient survival.
Clinical association of tumor clusters by pathway
deregulation score and overlap somatic mutations
We conducted the association study between the num-
ber of somatic nonsynonymous mutations from exome-
seq, mRNA-seq and the overlap between the two with
tumor stage and histological type, degree of differenti-
ation, and tumor clusters formed by pathway deregulation
score using Kruskal-Wallis test. The correlation of the
number of non-synonymous mutations from the above
three data with the mean pathway deregulation score was
performed by Pearson correlation. Kaplan-Meier survival
was applied to tumor hazard clusters by pathway deregu-
lation score; The Cox proportional model was utilized for
individual gene expression or number of mutations associ-
ated with survival.
Mutations validated by Lung/OncoCarta for
selected oncogenes
Among the 27 tumors, we conducted mutation validation
for 26 tumors using the combination of Lung/OncoCarta
panels (http://www.sequenom.com/). Mutations found
from those samples were compared with the data from
exome-seq and mRNA-seq. Only single nucleotide muta-
tions were used and compared in this study.
Results
Clinical and pathological characteristics of 27
never-smokers with adenocarcinoma
Among the 27 patients, 4 were male and 23 were female
with average age 66.1 (+/- 12.6). There were 4 bronchi-
alveolar adenocarcinomas (BAC) (reclassified as adeno-
carcinoma in situ according to 2011 ASLC/ATS/ERS
classification) and 23 adenocarcinomas (AD). All pa-
tients were in stage I, with 10 in IA and 17 in IB. Seven
patients died at the last follow-up, with average follow-
up time of 5.63 years (ranging from 0.36 to 11.96 years
with standard deviation of 2.64 years). Twenty tumors
were well-differentiated and 7 were moderately differenti-
ated (Table 1).
High agreement for SNVs called by exome and mRNA-seq
For each exome-seq sample, we generated an average of
168 million 100 bp paired end reads and 88% of reads
were aligned to genome and 47% were aligned to the tar-
geted regions (Agilent capture kit version 2, Additional
file 1 for sequence depth, alignment statistics and average
coverage for each individual sample). Very similarly for
mRNA-seq, on average there were 168 million pair-end
reads for each sample with alignment efficiency of 87%
(Additional file 2 for sequence depth, alignment statistics,
and number of genes detected with at least 1 tag and 1
RPKM for each individual sample from mRNA-seq). We
first compared the SNV call result from exome-seq and
mRNA-seq for each sample by SNVmix2 at the alternative
allele probability cut-off of 0.8. There were 13,292 –
21,413 genomic positions where both exome-seq and
mRNA-seq had SNVs, among which 99.88-99.98% had
the same alternative allele or SNVs (Additional file 3). The
high agreement confirmed the reliability of data and vari-
ant calling using either DNA or mRNA.
Somatic mutations in exome-seq data
In the 27 adenocarcinoma, we detected an average of
1,274 somatic mutations per tumor (ranging from 537 to
1,841), about 25 mutations per megabase. When we lim-
ited the mutations in the coding regions, the average
number of mutations in each tumor was 114 (45-322,
about 2 per megabase ranging from 1 to 6), among which
77 (25-237) were nonsynonymous mutations. The number
of mutations, either total number or nonsynonymous,
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were not associated with clinical and pathological vari-
ables (tumor subtype, stage, grade of differentiation, and
age at diagnosis). There were 1,756 unique functional
somatic mutations (non-synonymous or stop/gain/loss),
among which 132 (7.5%) were present in 2 or more sam-
ples involving 80 genes.
Somatic mutations in mRNA-seq data
For the mRNA-seq data, we detected an average of 957
(339-1,899) somatic single nucleotide mutations in each
tumor, among which about 131 (45-341) were in the
coding region and ~89 were non-synonymous (ranging
from 31 to 249). Again, the number of mutations, either
total number or nonsynonymous, was not significantly
associated with clinical and pathological variables. Among
the 27 adenocarcinomas, there were 2,198 unique func-
tional somatic mutations (non-synonymous or stop/gain/
loss), among which 167 (7.6%) were present in 2 or more
samples involving 126 genes.
Somatic mutations detected in both exome-seq and
mRNA-seq
Mutations present in both DNA and mRNA likely play a
bigger role in cancer genomics, thus we focused on all
coding region overlap mutations between DNA and
mRNA data. Surprisingly, the comparison generated a
small fraction of overlap somatic mutations between
DNA and mRNA, which varied from tumor to tumor
and accounted for 0-22% of RNA and 0-18% of DNA
mutations (Figure 1A). These mutations (298 in total)
involved 262 genes and most were nonsynonymous,
with the top mutated genes as EGFR (4 out of 27,
14.8%), TP53, KRAS and RPS6KB2 (all in 3 samples
with mutation frequency 11%). Other mutated genes
found in 2 samples include ATXN2, DHX9, PTPN13,
SP1, SPTAN1 and MYOF (Table 2, Additional file 4 for
all the overlap nonsynonymous mutations). All the
mutations in the 10 genes occurred at the exact same
genomic location with the same mutated allele between
the DNA and RNA.
Among the overlap mutations, the minimum mu-
tated allele frequency in either DNA or mRNA was 8%
(Figure 1B). For most mutations (240/282, 85%), the
mutated allele frequency was higher in mRNA than in
DNA, suggesting these mutations may have been pref-
erentially expressed in mRNA transcripts. For example,
EGFR mutation detected in 4 tumors all had a higher
mutation frequency in mRNA than in DNA (Figure 1B,
red highlight). Mutations in other 9 genes also had
higher frequencies in mRNA except one sample for ATXN2
and TP53 and another for RPS6KB2.
Mutations validated in Lung/OncoCarta panels
Among the 27 tumors, 26 were also tested by Lung/
OncoCarta for mutations in EGFR and KRAS. All 3 EGFR
(L858R) and 3 KRAS (Q61H and G12D) mutations de-
tected in both exome-seq and mRNA-seq were validated
by the assay.
Pathway enrichment for the genes with conserved
mutations
We conducted a pathway enrichment analysis for the
262 genes with mutations in both DNA and RNA using
IPA (http://www.ingenuity.com/). Twenty six pathways
showed a significant enrichment at p value less than 0.01.
Most of these pathways were involved in cancer develop-
ment or cancer processes (Additional file 5).
Table 1 Clinical and pathological information for 27
adenocarcinomas in the study
Tissueid Age Sex Stage Cell* Diff# Grade+ Status TTLF
Lu1031 57 Female IA AD Well II 0 8.59
Lu1050 58 Male IB AD Well II 0 7.54
Lu1068 57 Female IB AD Mod III 1 3.28
Lu106 63 Male IB AD Well II 0 11.96
Lu113 89 Female IA AD Well II 1 5.68
Lu1182 61 Female IA BAC Well II 0 8.24
Lu1321 68 Female IB AD Well II 0 6.75
Lu1377 64 Female IA AD Well II 0 0.36
Lu1405 54 Female IB AD Mod III 0 8.03
Lu1450 74 Female IB AD Well II 0 8.08
Lu1479 64 Female IA AD Well II 0 8.08
Lu1518 55 Female IB AD Mod III 0 8.01
Lu1606 88 Female IA AD Well II 0 6.75
Lu1659 71 Female IA AD Well II 1 4.09
Lu1682 74 Female IA AD Well II 1 3.60
Lu1790 73 Female IB AD Well II 0 6.20
Lu1821 32 Male IB AD Mod III 0 6.47
Lu1848 46 Female IB AD Well II 0 5.29
Lu1942 70 Male IB AD Mod III 1 1.38
Lu1943 82 Female IB AD Well II 1 5.99
Lu2029 58 Female IB AD Well II 0 6.46
Lu2040 79 Female IB AD Mod III 0 0.78
Lu2368 58 Female IB AD Mod III 1 2.98
Lu2499 74 Female IB BAC Well I 0 5.03
Lu2502 77 Female IA BAC Well II 0 5.13
Lu346 67 Female IA AD Well II 0 5.08
Lu587 72 Female IB BAC Well I 0 5.85
*Tumor cell subtype. AD-adenocarcinoma, BAC-bronchioalveolar carcinoma
(adenocarcinoma in situ according to 2011I ASLC/ATS/ERS classification).
+Grade – Mayo 4 level grade of differentiation. #Diff – summarized tumor degree
of differentiation from grade. I-II well, III- moderate, IV – Poorly/undifferentiated.
TTLF – time to last follow up in years; status – 1 death, 0 alive.
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Association of mutation load in DNA and RNA with
clinical variables
We tested the association between the total number of
nonsynonymous mutations detected in each sample, ei-
ther from exome-seq or mRNA-seq, and the clinical
variables of tumor stage, histological grade of differenti-
ation, sub cell type and found no significant association
for any of these variables. However, when the test was
done on the number of overlap nonsynonymous muta-
tions between exome-seq and mRNA-seq with these
Figure 1 Overlapping somatic mutations between exome-seq and mRNA-seq. A. The number of somatic mutations from exome-seq (blue),
mRNA-seq (green), and overlap between the two (red) for each tumor. B. Mutated allele frequency in tumor from exome and mRNA-seq. The
frequency is mostly higher and is preferentially expressed in mRNA. The red dot is for EGFR mutation in 4 tumors, all higher in mRNA. Green
line – linear trend line for the mutation allele frequency between DNA and mRNA. Black line – expected diagonal line if the frequencies were the
same between DNA and mRNA.
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variables, we found a significant higher number of muta-
tions in ADs (median of 9) than in BAC (median of 3,
Kruskal-Wallis rank sum test p value = 0.004, Additional
file 6).
The 10 genes with recurrent mutations function in a closely
related network
We conducted gene network analysis for the 10 genes
and all but MYOF were mapped to the same network of
“Cancer, gastrointestinal disease and respiratory disease”
(Additional file 7). Although not in the same network,
MYOF is involved in cell-to-cell signaling and interaction,
cellular and embryonic development. A recent data shows
high expression of this gene is associated with tumor mes-
enchymal transformation and aggressive phenotype [22].
Pathway deregulation scores are correlated with mutation
patterns of the 10 genes with recurrent mutations present
in both DNA and RNA and clinical outcomes
Unsupervised clustering using pathway deregulation scores
of 272 pathways showed that the tumors formed 2 main
clusters (Figure 2A), the left branch with 12 samples
(referred as Cluster 1) and the right with 15 samples.
The right cluster could be further separated into two
subclusters, one in the middle (Cluster2) with 4 samples
and another on the right with 11 samples (Cluster 3). The
Cluster 3 had a higher proportion of moderately differen-
tiated tumors (Fisher’s test p value 0.01) and a higher pro-
portion of patients who died of the disease (Fisher’s
p value 0.01). The cluster also had a higher number of
mutations (Fisher’s test p value 0.01) in the 10 genes
(EGFR, KRAS, TP53, PTPN13, RPS6KB2, SP1, SPTAN1,
ATXN2, DHX9, MYOF) with recurrent mutations in both
DNA and RNA. No association with patient survival was
found for patient age at lung cancer diagnosis, sex, tumor
stage (stage IA vs IB), histological cell subtype (AD vs.
BAC), histologic grade of differentiation. However, the
tumor clusters formed by pathway deregulation scores
were significantly associated with patient survival, either
by combined Cluster 1, 2 vs. Cluster 3 (log rank p value
0.002, Figure 2B), or among three clusters (p = 0.01). The
tumors in Cluster 3 had significantly a higher pathway de-
regulation score for majority of pathways than tumors in
Cluster 1 and 2 (shown in red in Figure 2A, positive score
difference in Figure 2C). The tumors with mutations in
any of the 10 genes rendered worse survival than the tu-
mors without mutations (log rank p value 0.02, Additional
file 8). With the increase of mutations in these genes, the
risk of death increased 2.6 fold (hazard ratio 2.55 with p
value 0.004).
Pathway mean deregulation score positively correlated
with the number of mutations in each sample
We conducted a correlation analysis between the number
of nonsynonymous mutations detected from exome-seq,
mRNA-seq, and the overlap between the two and found
that all were positively correlated with the mean pathway
deregulation score with correlation coefficient of 0.56,
0.61 and 0.80, respectively (Figure 3). The highest correl-
ation between the average pathway deregulation score and
the overlap mutations between DNA and RNA suggested
that the conserved mutations have more functional im-
pacts on pathway regulation and network interaction.
Expression pattern of the 10 recurrent genes in tumor
and normal lung and tumors with or without mutation
Compared to the normal lungs, RPS6KB2, TP53, EGFR,
DHX9, and MYOF were elevated and SPTAN1, ATXN2,
and SP1 were reduced in tumors. No significant change
was observed for KRAS and PTPN13 (Additional file 9).
When comparing the gene expression of the tumors with
or without mutations for each of the 10 genes, KRAS and
DHX9 showed higher expression (1.5 fold) in the tumors
with the mutation compared to those without the muta-
tion (Additional file 10). There was no expression differ-
ence for other genes.
Gene expression patterns of the 10 recurrent genes in
tumors with bad and good outcomes
Comparing the tumors in Cluster 3 (with bad outcome)
with the tumors in Cluster 1 and 2 (good outcome),
PTPN13 was significantly down expressed with 2.15
fold change while KRAS, SP1, and DHX9 were up-
expressed. No significant change was seen for other
genes (Additional file 11). In the Cox regression of sur-
vival analysis, PTPN13 and DHX9 were significantly asso-
ciated with survival with a hazard ratio of 0.28 (p value
0.02) and 13.3 (p value 0.04), respectively. The higher
expression of PTPN13 predicted a better survival and the
reverse was for DHX9. KRAS and SP1 were borderline
Table 2 Recurrent mutations detected in both exome- and
RNA-seq
Gene Number of samples













Genes with recurrent mutations. 15 out of 27 samples (55.6%) had one or
more mutations in 10 genes with recurrent mutations.
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significant (HR 4.7, p 0.07 and 4.9, p 0.09, respectively),
which both were associated with poor survival when
highly expressed. No association was observed for other 4
genes.
Discussion
Several exome or whole genome sequencing studies have
been conducted on lung adenocarcinoma with a small
number of never smokers included [4,7] with the aim to
find high impact and recurrent mutations. However,
results so far have not yielded significant progress.
Most of the reported mutations are either from a few
genes reported previously or the recurrent mutations
across samples are very low. In 27 adenocarcinomas of
never smokers [4], only three genes, EGFR, TBL3 and
HSD17B7P2, occurred in two or more samples. Even in
the larger dataset with 41 never smokers from TCGA,
only 8 genes are found with recurrent mutations
(C21orf99, FAM182B, CCDC144C, FLJ36000, DDX11L2,
EEF1B2, FRG1B, and EGFR; the level II somatic mutation
data for lung adenocarcinoma was downloaded from
TCGA at http://cancergenome.nih.gov in February 2013).
Surprisingly, only EGFR is the gene in common across the
studies and the biological relevance of other genes is little
known. Those studies are all performed on DNA and no
comparison is made with mutations at RNA and how the
mutations can interplay with RNA expression and tran-
scriptome network and pathway regulation remains a
question. As mutations detected from either DNA or
mRNA can contain artifacts from sequence or alignment
errors and passenger mutations are more enriched in
unexpressed genes [6], we hypothesized that mutations
present in both DNA and RNA or conserved mutations
were more likely legitimate and driver mutations for
tumor biology.
As expected, hundreds to thousands of somatic muta-
tions were detected at either exome or RNA sequencing
for each tumor. However, the number of mutations from
either was not associated with any clinical variables. The
mutations present in both DNA and mRNA were only
Figure 2 Association of pathway deregulation with mutation profiles and patient survival. A. Unsupervised clustering for tumors by
pathway deregulation score and their association with 10 genes with recurrent mutations. B. Kaplan Meier survival curve by sample cluster
defined by pathway deregulation score comparing Cluster 3 vs. Cluster 1, 2. C. Differentially deregulated pathways between patients with bad
(cluster 3) and those with good survivals (cluster 1 and 2). X-axis: mean pathway score difference. Y-axis: negative log10 p value. The samples with
bad survival had more pathways with a higher deregulation score.
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from tens to hundreds in each tumor. Collectively, these
mutations involved 261 genes and they were almost all
in the coding region and nonsynonymous. These genes
were highly enriched in tumorigenesis and cancer re-
lated pathways and networks while the genes with
functional mutations from either exome-seq (1,267
genes) or mRNA-seq (1,610 genes) were more related
to non-cancerous pathways (Additional files 12 and 13).
More importantly, we found 10 recurrently mutated genes
were highly concentrated in the group of tumors with more
deregulated pathways and worse survival. In addition to the
commonly mutated genes such as EGFR, KRAS, and TP53,
we found several genes not reported before and all involved
in tumor biology. PTPN13 a tumor suppressor is often
inactivated in non-small cell lung cancer due to the loss of
either mRNA and protein expression or somatic mutation
[23,24]. In this set of tumors, all from never smokers, we
did not see the significant differential expression com-
pared to their paired normal lung. However, the tumors
with lower expression of this gene had shorter survival
than the tumors with higher expression. RPS6KB2 (ribo-
somal protein S6 kinase beta-2) is a member of serione/
theonine kinases which regulate protein synthesis and
cell proliferation. The function gain of this gene is re-
ported in a subset of breast cancer, which is associated
with worse prognosis [25]. The genomic variants of this
gene are also found to be associated with the development
of colon cancer [26]. The up-regulation of this gene in
lung adenocarcinoma suggests its role in lung adenocar-
cinoma. SP1 is a transcription factor that regulates gene
expression and may promote tumor progression and lead
to bad outcome for patients as observed in our data. It
may be a potential treatment target for prostate cancer
[27]. DHX9 (DEAH (Asp-Glu-Ala-His) box helicase 9)
is an enzyme that catalyzes the ATP-dependent un-
winding of double-stranded RNA and DNA-RNA com-
plexes and functions as a transcriptional regulator. The
higher expression of this gene is associated worse out-
come in this set of patients. ATXN2 (ataxin 2) mutation is
associated with spinocerebellar ataxia type 2 and a recent
study shows that the methylation of this gene is one of the
nine genes that define clear-cell subtype of ovarian cancer.
MYOF (myoferlin) depletion in breast cancer cells has
shown to promote mesenchymal to epithelial transform-
ation and stall invasion [22] with potential as a biomarker
or drug target for metastatic cancer diagnosis and therapy
Figure 3 Correlation of average pathway deregulation score and number of exome, mRNA, and overlap mutations. The number of
overlap mutations in each tumor is highly correlated with average pathway deregulation score with a correlation coefficient 0.80 although the
number of mutations in either DNA or RNA is also moderately correlated with pathway deregulation.
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[28]. This gene is up-regulated in lung adenocarcinoma
and supports its role in tumor transformation. And
finically, SPTAN1 (spectrin, alpha, non-erythrocytic 1)
belongs to a family of filamentous cytoskeletal proteins
that function as essential scaffold proteins that stabilize the
plasma membrane and organize intracellular organelles.
This gene is implicated in DNA repair and cell cycle regu-
lation. The reduced expression in tumors may indicate its
compromised DNA repair function.
One of the strengths of our work is, instead of gene
level analysis, we used pathway deregulation scores for
each sample. This not only significantly reduced the di-
mensionality of the data but also put genes into functional
context as mutations in some genes may not necessarily
affect their own expression but disrupt protein-protein
interaction and pathway functions. As shown, the pathway
deregulation score was the best predictor for the tumor
behavior and these pathway dysfunctions may be contrib-
uted by tumor somatic mutations occurred in both DNA
and RNA. Either the average pathway deregulation score
or the number of conserved high impact mutations can
better predict patient outcomes. This may be potentially
used for clinical patient stratification.
We observed the high variability of the number of
overlap mutations between DNA and mRNA from
tumor to tumor and examined whether it was the result of
varied sequence depths. As this is dictated by the sample
with the lowest sequence depth, we plotted the relation-
ship of this with the number of overlap mutations and did
not see any correlation (Additional file 14), suggesting it
was not due the sequence depth difference but more likely
caused by the degree of tumor abnormality. For the
“mutations” called by mRNA-seq but not exome-seq in
the coding region, we found about 7% were not covered
or below the coverage threshold for somatic mutation
call in exome-seq; 10% were called as “germline” mutations;
66% without variants in both tumor and normal (or with
reference allele); and 4% as “somatic” but not reaching the
significant cut-off of p value < 0.05. Unsurprisingly, for the
“somatic mutations” called by exome-seq but not RNA-seq,
over 46% were not or below the coverage threshold (genes
not expressed); 42% as reference calls; 1% as “germline”,
and 2% as “somatic” but not significant at the threshold
cut-off (Additional file 15).
Our focus in this study was single nucleotide mutations.
It is likely that insertions/deletions (indels) also contribute
to the clinical phenotypes of the tumors. However, indel
detection is more challenging for mRNA-seq data. Even
for exome-seq data, longer indels are often missed by
commonly used algorithms. Additionally, indels rarely
occur in the same positions and the “recurrent” indels are
hard to define. The functional impacts from indels are also
difficult to predict. Along with copy number changes and
structural variants, further research will definitely extend
our understanding of the complex tumor biology of
adenocarcinoma in never smokers.
Conclusions
In summary, we identified highly clinical relevant recur-
rent mutations in 10 genes from never-smoker adenocar-
cinoma that are associated with pathway deregulation,
tumor phenotype and patient clinical outcomes. These
mutations are conserved and preferentially expressed in
RNA and are likely the driver for tumor biology and may
potentially be used for outcome prediction and treatment
targets.
Additional files
Additional file 1: Sequence depth, alignment statistics and average
coverage for exome-seq samples.
Additional file 2: Sequence depth, alignment statistics, and number
of genes detected for mRNA-seq samples.
Additional file 3: SNV agreement between exome-seq and mRNA-seq.
The number on the left Y axis is the number of sites commonly called by
both and blue bar marks the number for each sample (both tumor and its
pair normal are plotted for a total of 54 samples; only tumor sample name
is shown on X axis. The normal is right after paired tumor). The number on
the right Y axis is the percentage of agreement of SNV alternative allele calls
between exome and mRNA-seq with the brown line for each sample.
Additional file 4: Overlap mutations between DNA and mRNA. The
full list of overlap mutations between DNA and mRNA.
Additional file 5: Enriched pathways for the genes with overlap
mutations. List of enriched pathways using the genes with mutations
found in both DNA and RNA.
Additional file 6: Overlap mutations by cell type. “BAC” has fewer
mutations than adenocarcinoma. Y-axis. The number of overlap mutations
in log10 scale.
Additional file 7: The 10 recurrently mutated genes in a closely
related interaction network. The 10 genes but MYOF with recurrent
mutations are mapped to the same network of “Cancer, gastrointestinal
disease and respiratory disease”.
Additional file 8: Kaplan-Meier survival curve for tumors with or
without mutations in 10 genes with recurrent mutations. Tumors
with mutations in any of the genes have poor survival than those
without mutations.
Additional file 9: Differential expression between tumor and
normal for the genes with recurrent mutations from edgeR.
logFC – log2 fold change; FC – fold change; logCPM – normalized
average expression across tumor and normal sample in log2 scale;
PValue – differential p value between tumors and normal samples;
FDR – false discovery rate.
Additional file 10: The expression profiles of the 10 genes in 27
tumors. Bar graph for the gene expression of 10 genes with recurrent
mutations. X-axis – sample; y-axis – log2 RPKM expression. The black bars
are for sample with mutation.
Additional file 11: 10 gene expression in tumors with good and
bad outcome. The boxplot of expression of 10 genes with recurrent
mutation in the tumors of clusters 1, 2 (good outcome) and cluster 3
(bad outcome), respectively. Y-axis is the log2 RPKM expression.
Additional file 12: Enriched pathways for the genes with functional
somatic mutations from exome-seq.
Additional file 13: Enriched pathways for the genes with functional
somatic mutations from mRNA-seq.
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Additional file 14: Sequence depth vs. number of overlap
mutations between DNA and mRNA. No correlation is observed and
the tumor with the highest number of common mutations (Lu2368A)
has much lower sequence depth than most of samples. X-axis is the
minimum depth of tumor and normal from both exome-seq and
mRNA-seq. Y-axis is the number of overlap mutations.
Additional file 15: Backfill information of mutation positions of one
data in another. For the mutations called in DNA (or RNA) but not in
RNA (or DNA), the coverage and allele information for the genomic
positions in RNA (or DNA) are examined for potential genotype/mutation
calls and tabulated by category. For DNA mutations not called in RNA,
majority of them (46%) are lack of sufficient coverage (genes not
expressed) while majority of mutations called in RNA but not in DNA
(63%) do not have the mutation allele in the tumor DNA (or reference call).
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